Supplier profile
Roche Eesti Osaühing
Every public-sector award we hold for this supplier, across Estonia, from 20 May 2009 to 24 Sept 2026.
Awards won
135
all time
Attributed value
€59.2m
94 shared, unvalued
Buyers
13
public bodies
Active
2009–2026
first to latest award
Awards by year
Who they win from
| Buyer | Awards | Value |
|---|---|---|
| Aktsiaselts Ida-Tallinna Keskhaigla | 28 | €6.4m |
| Sihtasutus Tartu Ülikooli Kliinikum | 25 | €11.7m |
| sihtasutus Tartu Ülikooli Kliinikum | 20 | €161k |
| Aktsiaselts Lääne-Tallinna Keskhaigla | 18 | €2.1m |
| Sihtasutus Põhja-Eesti Regionaalhaigla | 17 | €28.6m |
| sihtasutus Põhja-Eesti Regionaalhaigla | 16 | €9.7m |
| Tervisekassa | 3 | not attributable |
| Kaitsevägi | 2 | €17k |
| Sihtasutus Tallinna Lastehaigla | 2 | not attributable |
| Eesti Haigekassa | 1 | not attributable |
What they win
Awards
Showing 26–50 of 135 awards we hold
- Estonia – Pharmaceutical products – Okrelizumab ↗Aktsiaselts Ida-Tallinna Keskhaiglaawarded 17 Sept 2024
- Estonia – Pharmaceutical products – Pertuzumab ↗Aktsiaselts Ida-Tallinna Keskhaiglaawarded 14 Sept 2024
- Estonia – Pharmaceutical products – Trastuzumab emtansiin ↗Aktsiaselts Ida-Tallinna Keskhaiglaawarded 14 Sept 2024
- Estonia – Pharmaceutical products – Kasvajavastased ja immunomoduleerivad ained ↗Aktsiaselts Ida-Tallinna Keskhaiglashared awardawarded 12 Jun 2024
- Estonia – Antineoplastic and immunomodulating agents – Immunosupressantide ja immunostimulaatorite ostmine ↗Aktsiaselts Lääne-Tallinna Keskhaiglashared awardawarded 4 Jun 2024
- Estonia – Pharmaceutical products – Atesolizumab s.c. ↗Aktsiaselts Ida-Tallinna Keskhaiglashared awardawarded 4 Jun 2024
- Estonia – Pharmaceutical products – Bioloogiliste ravimite ostmine ↗sihtasutus Tartu Ülikooli Kliinikumshared awardawarded 28 May 2024
- Estonia – Pharmaceutical products – Haiglaravimid - mai 2024 ↗sihtasutus Põhja-Eesti Regionaalhaiglashared awardawarded 25 May 2024
- Estonia – Pharmaceutical products – Haiglaravimid - aprill 2024 ↗sihtasutus Põhja-Eesti Regionaalhaiglashared awardawarded 26 Apr 2024
- Estonia – Pharmaceutical products – Antineoplastilised ravimid ↗sihtasutus Tartu Ülikooli Kliinikumshared awardawarded 6 Apr 2024
- Estonia – Pharmaceutical products – Monoklonaalsed antikehad, immuunosupressandid, teised astmavastased ained süsteemseks kasutamiseks, teised dermatoloogilised preparaadid 2 ↗sihtasutus Põhja-Eesti Regionaalhaiglashared awardawarded 19 Mar 2024
- Estonia – Medicinal products for the blood and blood-forming organs – Verejooksu tõkestavad ja aneemiavastased ravimid KORDUSHANGE ↗Aktsiaselts Lääne-Tallinna Keskhaiglashared awardawarded 2 Feb 2024
- Estonia – Pharmaceutical products – Haiglaravimid - jaanuar 2024 ↗sihtasutus Põhja-Eesti Regionaalhaiglashared awardawarded 29 Jan 2024
- Estonia – Pharmaceutical products – Monoklonaalsed antikehad, immuunosupressandid, teised astmavastased ained süsteemseks kasutamiseks, teised dermatoloogilised preparaadid ↗sihtasutus Põhja-Eesti Regionaalhaiglashared awardawarded 11 Jan 2024
- Estonia – Antineoplastic and immunomodulating agents – Antineoplastilised ja immuunosupresseerivad ravimid ↗sihtasutus Tartu Ülikooli Kliinikumshared awardawarded 15 Nov 2023
- Estonia – Medical solutions – Silmakirurgias kasutatavad ravimid/lahused ↗sihtasutus Tartu Ülikooli Kliinikumshared awardawarded 17 Oct 2023
- Estonia – Pharmaceutical products – Meeleelundite ravimid (S-grupp) ja oftalmoloogilised lahused ↗Aktsiaselts Ida-Tallinna Keskhaiglashared awardawarded 22 Aug 2023
- Estonia – Pharmaceutical products – Tervishoiuteenuste osutamisel kasutatavad ravimid ↗sihtasutus Tartu Ülikooli Kliinikumshared awardawarded 6 Jul 2023
- Estonia – Pharmaceutical products – Ravimid tsefoksitiin, ipilimumab, okrelizumab ja immuunoglobuliin intravaskulaarseks kasutamiseks ↗sihtasutus Põhja-Eesti Regionaalhaiglashared awardawarded 4 Jul 2023
- Estonia – Pharmaceutical products – Atesolizumab, ipilimumab ja nivolumab ↗Aktsiaselts Ida-Tallinna Keskhaiglashared awardawarded 9 May 2023
- Estonia-Tartu: Pharmaceutical products ↗sihtasutus Tartu Ülikooli Kliinikumshared awardawarded 5 Apr 2023
- Estonia-Tallinn: Pharmaceutical products ↗Aktsiaselts Ida-Tallinna Keskhaiglashared awardawarded 15 Mar 2023
- Estonia-Tallinn: Pharmaceutical products ↗Sihtasutus Tallinna Lastehaiglashared awardawarded 28 Feb 2023
- Estonia-Tallinn: Pharmaceutical products ↗Aktsiaselts Ida-Tallinna Keskhaiglashared awardawarded 22 Feb 2023
- Estonia-Tallinn: Pharmaceutical products ↗Eesti Haigekassashared awardawarded 6 Feb 2023
Bidding against them?
Get new tenders in their space in a daily digest, scored against your own capability — plus the full notice behind each of these awards, with the documents and contacts it published.
Start 7-day free trialHow this profile is built
Awards are collected from official public procurement notices and deduplicated so one procurement counts once. Supplier names are grouped across their published spellings: case and punctuation are ignored, and “Ltd” is treated as optional because buyers routinely leave it off. Everything else that marks a different organisation is kept — an LLP, a plc, a CIC and a Teoranta are separate businesses from a Ltd of the same name, as are a parent and a named subsidiary, and none of them are merged here. Where another entry differs from this one only by legal form or a bracketed qualifier it is listed above as possibly the same organisation — a hint for the reader, never a merge: figures are per legal entity and never combined. Value is attributed only where the notice is explicit: the supplier's own itemised amount, or the whole value where they were the sole named supplier. Awards naming several suppliers without a published split are counted and marked shared, never valued, and a framework ceiling is never treated as money any one appointed supplier won. Sterling and euro are never added together. The linked source notice is authoritative.
Company pages are for organisations. If this page profiles you as an individual — a sole trader or an individual contractor — you can ask for it to be withheld: see how.